Company Overview of Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company’s lead product candidate is the ADS-5102 that is in Phase 3 clinical development for the treatment of levodopa-induced dyskinesia, a movement disorder associated with Parkinson’s disease; and in a Phase 2 clinical study for the treatment of symptoms associated with various sclerosis, including walking impairment. The company’s portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release ca...
1900 Powell Street
Emeryville, CA 94608
Founded in 2000
Key Executives for Adamas Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Total Annual Compensation: $770.0K
Senior Vice President of Product Development
Total Annual Compensation: $503.0K
Chief Medical Officer
Total Annual Compensation: $313.9K
Compensation as of Fiscal Year 2015.
Adamas Pharmaceuticals, Inc. Key Developments
Adamas Appoints Michael F. Bigham to Board of Directors
Sep 22 16
Adamas Pharmaceuticals, Inc. announced the appointment of Michael F. Bigham, Chairman and Chief Executive Officer of Paratek Pharmaceuticals, Inc., to its Board of Directors. Mr. Bigham has broad management experience with over 25 years of senior leadership in the biotechnology industry.
Allergan plc and Adamas Pharmaceuticals, Inc. Announce U.S. Availability of New Dosage Strengths for NAMZARIC Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease
Sep 22 16
Allergan plc and Adamas Pharmaceuticals, Inc. announced that all four dosage strengths of NAMZARIC (memantine and donepezil hydrochlorides) extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmacies throughout the U.S. NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI) for the treatment of moderate to severe Alzheimer's Disease in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC'S new indication and dosage strengths were approved by the U.S. Food and Drug Administration (FDA) in July 2016. Approximately 75% of patients diagnosed with Alzheimer's Disease are in the moderate to severe stage of the disease and yet only about one-third of these patients are treated with combination therapy. Clinical studies have shown that combination therapy with Namenda XR and an AChEI such as Aricept demonstrated significantly superior improvement in cognition and global function verses an AChEI alone. NAMZARIC will be commercially available in 30 count bottles in 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg and 28 mg/10 mg. NAMZARIC is covered broadly by Medicare Part D prescription plans. The efficacy and safety of the coadministration of memantine HCl extended release and acetylcholinesterase inhibitors (AChEIs), including donepezil HCl, was based on the results of a randomized, double-blind, placebo-controlled trial of 677 patients with moderate to severe Alzheimer's Disease on a stable dose of AChEIs. The clinical study was not conducted with Namzaric; however, bioequivalence of Namzaric with coadministered memantine HCl extended release and donepezil HCl was demonstrated. Approximately 68% of the patients randomized to receive either memantine HCl extended release 28 mg or placebo were taking donepezil as the AChEI at Baseline and throughout the study. The results of this study, demonstrated statistically significant improvement in cognition and global function for patients treated with NAMENDA XR (memantine HCl extended release) 28 mg plus an AChEI compared to placebo plus an AChEI at 24 weeks.
Adamas Pharmaceuticals, Inc. Announces Two Data Presentations on ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia At the 4th World Parkinson Congress
Sep 12 16
Adamas Pharmaceuticals, Inc. announced details regarding two poster presentations highlighting data from EASE LID and EASE LID 3, two completed trials from the company's Phase 3 clinical program of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease, to be presented at the 4th World Parkinson Congress (WPC) being held in Portland, Oregon, September 20 to 23, 2016. Adamas Phase 3 clinical program of ADS-5102 for the treatment of LID comprises three placebo-controlled trials: EASED, EASE LID and EASE LID 3. These trials enrolled a total of 286 patients, of which 122 patients received a 340 mg dose of ADS-5102 once daily before bedtime for a pre-specified period of time. In all three trials, changes in LID versus placebo were assessed by the Unified Dyskinesia Rating Scale (UDysRS): week 8 (EASED), week 12 and week 24 (EASE LID) and week 12 (EASE LID 3). EASE LID 2, an open-label safety study open to patients from EASED, EASE LID and EASE LID 3 and to LID patients who have undergone deep brain stimulation, is ongoing.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|